Redeye endorses the results from ISAB’s first-in-human clinical study of its PreciseInhale system. The results unlock opportunities (after regulatory approval) in the clinical market, valued at around SEK5bn. We look forward to hearing more about the company’s planned process and reiterate our base case of SEK16.5.

Link to the analysis